Trial Profile
ADYNOVATE Drug Use-Results Survey
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Dec 2023
Price :
$35
*
At a glance
- Drugs Rurioctocog alfa pegol (Primary)
- Indications Haemophilia A
- Focus Adverse reactions; Therapeutic Use
- Sponsors Shire; Takeda
- 06 Apr 2023 Status changed from recruiting to completed.
- 02 Mar 2022 Planned End Date changed from 31 Jan 2022 to 31 Jan 2023.
- 02 Mar 2022 Planned primary completion date changed from 31 Jan 2022 to 31 Jan 2023.